RNA Small Molecule Drugs

The recognition that RNAs play roles beyond coding for proteins, influencing disease states, has unveiled a plethora of uncharted therapeutic targets. The discrete secondary and tertiary structures adopted by many RNAs fulfill essential biological functions and present unique pockets and grooves suitable for small molecule binding. Additionally, the inhibition of translation and the deactivation of noncoding RNA structures are mechanisms through which RNA-targeted small molecules can combat disease. These new realizations have spurred a surge in interest to develop small molecules that can selectively target these structured RNAs, potentially leading to treatments for conditions that have eluded traditional drug discovery approaches.

Jubilant Biosys services include development of custom-tailored screening platform that includes high-throughput screening and structure-activity relationship (SAR) support. We can support our clients in development and application of multiple approaches to study RNA – small molecule interaction and the dependent phenotypic outcome.